Zydus Lifesciences Limited has informed the Exchange about change in Management

Management Changes View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.8%Reaction day

₹985.50

prior close

₹987.85

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)-0.9%+0.1% vs market

Pharmaceuticals peers, median of 148sector-1.0%+0.2% vs sector

On the reaction day the stock moved 0.1 pts more than Nifty 100 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-1.2

15m

-1.4

30m

-1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.8-0.9+0.1-1.0+0.2

Next day

-0.3-1.2+1.0-1.1+0.8

+0.5-0.3+0.9-0.1+0.6

+0.7-0.4+1.1-0.3+1.0

+2.5+0.2+2.4+0.6+1.9

+2.8+0.2+2.7+0.0+2.8

+2.5+0.3+2.1+0.4+2.1

15d

+6.5+3.0+3.5+1.8+4.7

+1.0+0.0+1.0-2.1+3.1

+1.8+4.8-3.0-2.4+4.1

-4.6+5.6-10.2-5.5+0.9

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus Lifesciences has informed the exchanges about the passing away of Mr. Samir Desai, who served as President of the Biologics business unit and was part of the company's Senior Management. He ceased to be a part of Senior Management with effect from August 26, 2025. The company has disclosed this under SEBI's Listing Regulations (Regulation 30) with details attached as Annexure A. No other leadership changes or financial details were shared in this filing.

Likely market impact

This is a personnel change due to an unfortunate demise, not a governance or financial event. Investors should watch for any subsequent announcements about succession planning for the Biologics business unit, but there is no immediate impact on operations or financials expected from this disclosure alone.